Mizollibin Therapy for Pigmented Villonodular Synovitis or Giant cell tumor of tendon sheath

Mizollibin Therapy for Pigmented Villonodular Synovitis or Giant cell tumor of tendon sheath - MTPVNS

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004056

Enrollment

Registered

2010-08-17

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pigmented villonodular synovitis or giant cell tumor of tendon sheath

Interventions

Mizollibin 100mg-300mg/1 every day or every other day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pigmented villonodular synovitis or giant cell tumor of tendon sheath

Exclusion criteria

Exclusion criteria: Past history of mizollibin sensitivity WBC count<3,000/mm3 Pregnant women

Design outcomes

Primary

Measure	Time frame
to compare the extent of invasion in pigmented villonodular synovitis or giant cell tumor of tendon sheath roentgraphically between the start and end of the trial.	—

Countries

Japan

Contacts

Public ContactMasahiko Suzuki

Graduate School of Medicine, Chiba University Orthopaedic Surgery

masahiko@faculty.chiba-u.jp043-226-2117

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026